Finance
BioNTech guides for worse-than-expected 2025 revenue decline
Published by Global Banking & Finance Review®
Posted on March 10, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 10, 2025
1 min readLast updated: January 24, 2026
BioNTech anticipates a significant revenue drop for 2025, with projections falling below analyst expectations, affecting its stock price.
FRANKFURT (Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its share price.
The guidance compares with revenues of 2.75 billion euros reported for last year and with an average analyst estimate of about 2.5 billion for 2025, according to LSEG data.
The biotech firm's German traded stock was down 4.1% at 1110 GMT.
($1 = 0.9213 euros)
(Reporting by Ludwig Burger, editing by Thomas Seythal)
BioNTech projected its 2025 revenues to fall between 1.7 billion euros and 2.2 billion euros.
The guidance for 2025 is a decline from the 2.75 billion euros reported for the previous year.
Following the announcement, BioNTech's stock was down 4.1% at 1110 GMT.
Analysts had an average estimate of about 2.5 billion euros for BioNTech's 2025 revenues.
The article noted that $1 is equivalent to 0.9213 euros.
Explore more articles in the Finance category
